| Year |
Citation |
Score |
| 2013 |
Smardova J, Liskova K, Ravcukova B, Kubiczkova L, Sevcikova S, Michalek J, Svitakova M, Vybihal V, Kren L, Smarda J. High frequency of temperature-sensitive mutants of p53 in glioblastoma. Pathology Oncology Research : Por. 19: 421-8. PMID 23536279 DOI: 10.1007/s12253-012-9596-7 |
0.47 |
|
| 2012 |
Faltejskova P, Besse A, Sevcikova S, Kubiczkova L, Svoboda M, Smarda J, Kiss I, Vyzula R, Slaby O. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. International Journal of Colorectal Disease. 27: 1401-8. PMID 22476768 DOI: 10.1007/s00384-012-1461-3 |
0.467 |
|
| 2003 |
Bryja V, Sedlácek J, Zahradnícková E, Sevcíková S, Pacherník J, Soucek K, Hofmanová J, Kozubík A, Smarda J. Lipoxygenase inhibitors enhance tumor suppressive effects of jun proteins on v-myb-transformed monoblasts BM2. Prostaglandins & Other Lipid Mediators. 72: 131-45. PMID 14674625 |
0.5 |
|
| 2002 |
Kizek R, Trnková L, Sevcíková S, Smarda J, Jelen F. Silver electrode as a sensor for determination of zinc in cell cultivation medium. Analytical Biochemistry. 301: 8-13. PMID 11811961 DOI: 10.1006/abio.2001.5484 |
0.477 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Vlachová M, Gregorová J, Vychytilová-Faltejsková P, Gabło NA, Radová L, Pospíšilová L, Almáši M, Štork M, Knechtová Z, Minařík J, Popková T, Jelínek T, Hájek R, Pour L, Říhová L, et al. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. International Journal of Molecular Sciences. 23. PMID 36499093 DOI: 10.3390/ijms232314765 |
0.282 |
|
| 2014 |
Svachova H, Kryukov F, Kryukova E, Sevcikova S, Nemec P, Greslikova H, Rihova L, Kubiczkova L, Hajek R. Nestin expression throughout multistep pathogenesis of multiple myeloma. British Journal of Haematology. 164: 701-9. PMID 24329895 DOI: 10.1111/bjh.12689 |
0.246 |
|
| 2022 |
Gregorova J, Vychytilova-Faltejskova P, Kramarova T, Knechtova Z, Almasi M, Stork M, Pour L, Kohoutek J, Sevcikova S. Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients. Neoplasma. 69: 412-424. PMID 35037760 DOI: 10.4149/neo_2021_210527N715 |
0.239 |
|
| 2013 |
Slaby O, Sachlova M, Brezkova V, Hezova R, Kovarikova A, Bischofová S, Sevcikova S, Bienertova-Vasku J, Vasku A, Svoboda M, Vyzula R. Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer. Nutrition and Cancer. 65: 247-54. PMID 23441612 DOI: 10.1080/01635581.2013.756530 |
0.234 |
|
| 2015 |
Stankova M, Kubaczkova V, Sedlarikova L, Sevcikova S. Circulating microRNA as Biomarkers in Hematological Malignancies. Exs. 106: 123-38. PMID 26608201 DOI: 10.1007/978-3-0348-0955-9_5 |
0.21 |
|
| 2015 |
Fiserova B, Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. The miR-29 family in hematological malignancies. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 159: 184-91. PMID 25004911 DOI: 10.5507/bp.2014.037 |
0.207 |
|
| 2014 |
Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 99: 511-8. PMID 24241494 DOI: 10.3324/haematol.2013.093500 |
0.192 |
|
| 2017 |
Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S. Cell-free DNA - Minimally invasive marker of hematological malignancies. European Journal of Haematology. 99: 291-299. PMID 28692178 DOI: 10.1111/ejh.12925 |
0.188 |
|
| 2013 |
Kryukov F, Dementyeva E, Kubiczkova L, Jarkovsky J, Brozova L, Petrik J, Nemec P, Sevcikova S, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics. 102: 243-9. PMID 23831116 DOI: 10.1016/j.ygeno.2013.06.007 |
0.187 |
|
| 2015 |
Sedlarikova L, Kubiczkova L, Kryukov F, Pelcova J, Adam Z, Pour L, Hajek R, Sevcikova S. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 159: 554-61. PMID 24993743 DOI: 10.5507/bp.2014.035 |
0.182 |
|
| 2022 |
Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201226. PMID 36315921 DOI: 10.1200/JCO.22.01226 |
0.178 |
|
| 2019 |
Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews. 34: 56-66. PMID 30501907 DOI: 10.1016/j.blre.2018.11.003 |
0.174 |
|
| 2015 |
Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Plos One. 10: e0137294. PMID 26389804 DOI: 10.1371/journal.pone.0137294 |
0.172 |
|
| 2018 |
Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V, Stork M, Pour L, Sevcikova S. Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies. Hematological Oncology. 36: 786-791. PMID 30144133 DOI: 10.1002/hon.2554 |
0.165 |
|
| 2021 |
Stork M, Bezdekova R, Kralova R, Sandecka V, Adam Z, Krejci M, Boichuk I, Knechtova Z, Brozova L, Sevcikova S, Rihova L, Pour L. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant. Neoplasma. PMID 33618517 DOI: 10.4149/neo_2021_200814N861 |
0.165 |
|
| 2019 |
Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R. Long Non-Coding RNAs in Multiple Myeloma. Non-Coding Rna. 5. PMID 30682861 DOI: 10.3390/ncrna5010013 |
0.163 |
|
| 2013 |
Dementyeva E, Kryukov F, Kubiczkova L, Nemec P, Sevcikova S, Ihnatova I, Jarkovsky J, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. Journal of Translational Medicine. 11: 77. PMID 23522059 DOI: 10.1186/1479-5876-11-77 |
0.162 |
|
| 2012 |
Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master. Journal of Translational Medicine. 10: 183. PMID 22943793 DOI: 10.1186/1479-5876-10-183 |
0.158 |
|
| 2022 |
Stork M, Sevcikova S, Jelinek T, Minarik J, Radocha J, Pika T, Pospisilova L, Spicka I, Straub J, Pavlicek P, Jungova A, Knechtova Z, Sandecka V, Maisnar V, Hajek R, et al. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10. PMID 36289797 DOI: 10.3390/biomedicines10102535 |
0.154 |
|
| 2015 |
Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M, Pour L, Hajek R. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 159: 288-93. PMID 25877407 DOI: 10.5507/bp.2015.014 |
0.146 |
|
| 0 |
Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, Hájek R, Vasku A, Sevcikova S. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients. Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti. 31: 213-229. PMID 30441975 DOI: 10.14735/amko2018213 |
0.142 |
|
| 2022 |
Adam Z, Pour L, Tomíška M, Starý K, Horváth T, Doubková M, Nebeský T, Řehák Z, Koukalová R, Krejčí M, Krejčí M, Boichuk I, Štork M, Ševčíková S, Adamová Z, et al. Langerhans cell histiocytosis (LCH). Overview of symptoms of LCH, which may lead the patients to any of these medical specialists. Vnitrni Lekarstvi. 68: 11-21. PMID 36208940 |
0.142 |
|
| 2021 |
Gregorova J, Vychytilova-Faltejskova P, Sevcikova S. Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development. Cancers. 13. PMID 33809566 DOI: 10.3390/cancers13061333 |
0.142 |
|
| 2017 |
Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, Bezdekova R, Stork M, Adam Z, Pour L, Krejci M, ... ... Sevcikova S, et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. European Journal of Haematology. 99: 223-233. PMID 28543758 DOI: 10.1111/ejh.12908 |
0.142 |
|
| 2014 |
Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine. 18: 947-61. PMID 24712303 DOI: 10.1111/jcmm.12279 |
0.139 |
|
| 2018 |
Steiner N, Hajek R, Sevcikova S, Borjan B, Untergasser G, Göbel G, Gunsilius E. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research. 38: 5087-5092. PMID 30194153 DOI: 10.21873/anticanres.12828 |
0.139 |
|
| 2016 |
Kutálková K, Sedlaříková L, Adam Z, Ševčíková S. [Gene mutations connected to Waldenstöm macroglobulinemia]. Vnitrni Lekarstvi. 62: 40-3. PMID 26967235 |
0.135 |
|
| 2015 |
Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S. MicroRNAs in urine are not biomarkers of multiple myeloma. Journal of Negative Results in Biomedicine. 14: 16. PMID 26399230 DOI: 10.1186/s12952-015-0035-7 |
0.134 |
|
| 2013 |
Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leukemia & Lymphoma. 54: 189-91. PMID 22712836 DOI: 10.3109/10428194.2012.704030 |
0.133 |
|
| 2023 |
Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, Pavlicek P, Pospisilova L, Sedlak F, Straub J, Pika T, Knechtova Z, Fidrichova A, Boichuk I, Sevcikova S, et al. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis. Annals of Hematology. 102: 1501-1511. PMID 37088816 DOI: 10.1007/s00277-023-05188-4 |
0.13 |
|
| 2012 |
Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leukemia Research. 36: 1218-24. PMID 22727252 DOI: 10.1016/j.leukres.2012.05.010 |
0.13 |
|
| 2021 |
Bútová R, Vychytilová-Faltejsková P, Gregorová J, Radová L, Almáši M, Bezděková R, Brožová L, Jarkovský J, Knechtová Z, Štork M, Pour L, Ševčíková S. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. 9. PMID 34829867 DOI: 10.3390/biomedicines9111637 |
0.129 |
|
| 2021 |
Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, et al. Identification of patients at high risk of secondary extramedullary multiple myeloma development. British Journal of Haematology. PMID 34726261 DOI: 10.1111/bjh.17925 |
0.129 |
|
| 2018 |
Steiner N, Müller U, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Pircher A, Gunsilius E. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. Plos One. 13: e0202045. PMID 30096165 DOI: 10.1371/journal.pone.0202045 |
0.127 |
|
| 2010 |
Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. The Journal of Experimental Medicine. 207: 2581-94. PMID 21059853 DOI: 10.1084/Jem.20091071 |
0.126 |
|
| 2021 |
Bezdekova R, Jelinek T, Kralova R, Stork M, Polackova P, Vsianska P, Brozova L, Jarkovsky J, Almasi M, Boichuk I, Knechtova Z, Penka M, Pour L, Sevcikova S, Hajek R, et al. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. British Journal of Haematology. PMID 34500493 DOI: 10.1111/bjh.17713 |
0.126 |
|
| 2013 |
Kryukov F, Nemec P, Dementyeva E, Kubiczkova L, Ihnatova I, Budinska E, Jarkovsky J, Sevcikova S, Kuglik P, Hajek R. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leukemia & Lymphoma. 54: 1982-8. PMID 23323949 DOI: 10.3109/10428194.2013.764416 |
0.122 |
|
| 2016 |
Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. European Journal of Haematology. 97: 93-100. PMID 26432667 DOI: 10.1111/ejh.12688 |
0.12 |
|
| 2022 |
Minařík J, Ševčíková S. Immunomodulatory Agents for Multiple Myeloma. Cancers. 14. PMID 36497241 DOI: 10.3390/cancers14235759 |
0.12 |
|
| 2021 |
Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, Krejci M, Knechtova Z, Kral Z. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Annals of Hematology. PMID 34309714 DOI: 10.1007/s00277-021-04594-w |
0.118 |
|
| 2014 |
Paszekova H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S. High-risk multiple myeloma: different definitions, different outcomes? Clinical Lymphoma, Myeloma & Leukemia. 14: 24-30. PMID 24225331 DOI: 10.1016/j.clml.2013.09.004 |
0.116 |
|
| 2016 |
Adam Z, Pour L, Krejčí M, Vetešníková E, Sandecká V, Štork M, Čermáková Z, Pourová E, Ševčíková S, Král Z, Mayer J. [Pomalidomide in the treatment of multiple myeloma - own experience and overview of literature]. Vnitrni Lekarstvi. 62: 962-968. PMID 28139124 |
0.113 |
|
| 2020 |
Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, Kubaczkova V, Brožová L, Jarkovsky J, Plonkova H, Jelinek T, Sandecka V, Stork M, Pour L, Sevcikova S, et al. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. European Journal of Haematology. 104: 190-197. PMID 31763708 DOI: 10.1111/ejh.13358 |
0.113 |
|
| 2007 |
Lee BD, Sevcikova S, Kogan SC. Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leukemia Research. 31: 1131-4. PMID 17184839 DOI: 10.1016/j.leukres.2006.11.012 |
0.112 |
|
| 2021 |
Sandecká V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Heindorfer A, Pavlíček P, Sýkora M, Jungová A, Kessler P, Wróbel M, Starostka D, Ullrychová J, Stejskal L, et al. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology. PMID 34272773 DOI: 10.1111/ejh.13683 |
0.107 |
|
| 2016 |
Adam Z, Starý K, Kubinyi J, Zajíčková K, Řehák Z, Koukalová R, Tomíška M, Doubková M, Prášek J, Pourová E, Čermáková Z, Pour L, Krejčí M, Sandecká V, Ševčíková E, et al. [Hypercalcemia, symptoms, differential diagnostics and treatment, or importance of calcium investigation]. Vnitrni Lekarstvi. 62: 370-383. PMID 27319230 |
0.105 |
|
| 2013 |
Omidvar N, Maunakea ML, Jones L, Sevcikova S, Yin B, Himmel KL, Tennant TR, Le Beau MM, Largaespada DA, Kogan SC. PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica. 98: 424-7. PMID 23144197 DOI: 10.3324/Haematol.2011.057067 |
0.103 |
|
| 2014 |
Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 99: 360-4. PMID 24038024 DOI: 10.3324/haematol.2013.094409 |
0.103 |
|
| 2020 |
Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, Minařík J, Pavlíček P, Radocha J, Heindorfer A, Jelínek T, Stejskal L, Brožová L, Ševčíková S, Straub J, et al. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. British Journal of Haematology. PMID 32163180 DOI: 10.1111/bjh.16572 |
0.1 |
|
| 2023 |
Pečinka L, Vlachová M, Moráň L, Gregorová J, Porokh V, Kovačovicová P, Almáši M, Pour L, Štork M, Havel J, Ševčíková S, Vaňhara P. Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry. Journal of the American Society For Mass Spectrometry. 34: 2646-2653. PMID 37994781 DOI: 10.1021/jasms.3c00166 |
0.097 |
|
| 2016 |
Adam Z, Petrášová H, Řehák Z, Koukalová R, Krejčí M, Pour L, Vetešníková E, Čermák A, Ševčíková S, Szturz P, Král Z, Mayer J. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature]. Vnitrni Lekarstvi. 62: 820-832. PMID 27900869 |
0.096 |
|
| 2016 |
Adam Z, Szturz P, Krejčí M, Koukalová R, Michalková E, Řehák Z, Pourová E, Pour L, Volfová P, Sandecká V, Čermáková Z, Křen L, Sokol F, Hanke I, Penka I, et al. [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature]. Vnitr̆Ní LéKar̆Ství. 62: 287-98. PMID 27250606 |
0.094 |
|
| 2019 |
Deulofeu M, Kolářová L, Salvadó V, María Peña-Méndez E, Almáši M, Štork M, Pour L, Boadas-Vaello P, Ševčíková S, Havel J, Vaňhara P. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Scientific Reports. 9: 7975. PMID 31138828 DOI: 10.1038/s41598-019-44215-1 |
0.093 |
|
| 2023 |
Sandecka V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Pavlíček P, Jungová A, Kessler P, Wróbel M, Štork M, Štraub J, Pika T, Čápková L, Ševčíková S, et al. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. Neoplasma. 69: 1474-1479. PMID 36591805 DOI: 10.4149/neo_2022_220813N827 |
0.09 |
|
| 2012 |
Buresova I, Cumova J, Kovarova L, Stossova J, Dementyeva E, Kryukov F, Sevcikova S, Svachova H, Hajek R. Bone marrow plasma cell separation - validation of separation algorithm. Clinical Chemistry and Laboratory Medicine. PMID 23095232 DOI: 10.1515/cclm-2011-0837 |
0.088 |
|
| 2012 |
Buresova I, Cumova J, Kovarova L, Stossova J, Dementyeva E, Kryukov F, Sevcikova S, Svachova H, Hajek R. Bone marrow plasma cell separation - validation of separation algorithm. Clinical Chemistry and Laboratory Medicine. 50: 1139-40. PMID 22706262 DOI: 10.1515/cclm-2012-8837 |
0.088 |
|
| 2015 |
Kubiczkova Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, Pelcova J, Minarik J, Pika T, Pikalova Z, Scudla V, Krejci M, Adam Z, Pour L, Hajek R, ... Sevcikova S, et al. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. American Journal of Hematology. 90: E51-2. PMID 25428891 DOI: 10.1002/ajh.23910 |
0.086 |
|
| 2013 |
Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, et al. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clinical Lymphoma, Myeloma & Leukemia. 13: 123-30. PMID 23291040 DOI: 10.1016/j.clml.2012.11.012 |
0.086 |
|
| 2022 |
Adam Z, Zeman D, Čermák A, Dastych M, Doubková M, Horváth T, Skorkovská Š, Adamová Z, Řehák Z, Koukalová R, Pour L, Štork M, Krejčí M, Sandecká V, Ševčíková S, et al. IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease. Vnitrni Lekarstvi. 68: 4-19. PMID 36283812 DOI: 10.36290/vnl.2022.070 |
0.084 |
|
| 2016 |
Adam Z, Šedivá A, Koukalová R, Řehák Z, Petrášová H, Szturz P, Adamová Z, Vetešníková E, Pour L, Krejčí M, Sandecká V, Pourová E, Čermáková Z, Ševčíková S, Král Z, et al. [Schnitzlers SyndromeDifferential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra]. Vnitrni Lekarstvi. 62: 713-727. PMID 27715073 |
0.082 |
|
| 2021 |
Adam Z, Tomíška M, Řehák Z, Koukalová R, Krejčí M, Král Z, Adamová Z, Ševčíková S, Pour L, Štork M, Krejčí M, Sandecká V. Transformation of IgM-MGUS into Waldenström´s macroglobulinemia in two of six patients treated for Schnitzler´s syndrome. Vnitrni Lekarstvi. 67: 15-23. PMID 34171947 |
0.081 |
|
| 2016 |
Adam Z, Pour L, Krejčí M, Ševčíková S, Pourová E, Ševčíková E, Král Z, Mayer J. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitrni Lekarstvi. 62: 25-39. PMID 26967234 |
0.078 |
|
| 2017 |
Steiner N, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Untergasser G, Gunsilius E. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. Plos One. 12: e0181487. PMID 28727816 DOI: 10.1371/journal.pone.0181487 |
0.076 |
|
| 2022 |
Adam Z, Brančiková D, Romanová G, Pour L, Krejčí M, König J, Nebeský T, Adamová Z, Štork M, Krejčí M, Ševčíková S, Eid M, Sandecká V, Král Z. Hereditary hemorrhagic telangiectasia (OslerWeberRendu syndrome) - Part II. Pharmacological therapy and international guidelines for the therapy 2020. Vnitrni Lekarstvi. 67: 419-424. PMID 35459360 |
0.075 |
|
| 2022 |
Adam Z, Brančiková D, Romanová G, Pour L, Krejčí M, König J, Nebeský T, Adamová Z, Štork M, Krejčí M, Ševčíková S, Eid M, Král Z. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) Part I. Pathophysiology, clinical symptoms and recommend screening for vascular malformations. Vnitrni Lekarstvi. 67: 339-344. PMID 35459376 |
0.072 |
|
| 2016 |
Adam Z, Pourová E, Pour L, Michalková E, Krejčí M, Koukalová R, Řehák Z, Vaníček J, Nebeský T, Petrášová H, Ševčíková S, Mašek M, Král Z, Čermák A. [The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patients age or multiple myeloma?]. Vnitr̆Ní LéKar̆Ství. 62: 114-24. PMID 27172438 |
0.072 |
|
| 2019 |
Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Reviews. 36: 32-39. PMID 31005420 DOI: 10.1016/j.blre.2019.04.002 |
0.067 |
|
| 2021 |
Král Z, Řehák Z, Krejčí M, Koukalová R, Ševčíková S, Pour L, Krejčí M, Štork M, Sandecká V, Adam Z. Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy. Vnitrni Lekarstvi. 67: 157-164. PMID 34171955 |
0.065 |
|
| 2017 |
Hájek R, Sandecká V, Adam Z, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, et al. A first czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology. PMID 28384387 DOI: 10.1111/ejh.12894 |
0.062 |
|
| 2011 |
Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, Pika T, Pour L, Radocha J, Scudla V, Svachova H, Hajek R. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clinical Lymphoma, Myeloma & Leukemia. 11: 414-20. PMID 21859556 DOI: 10.1016/j.clml.2011.03.024 |
0.051 |
|
| 2021 |
Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. PMID 34247197 DOI: 10.1038/s41375-021-01343-w |
0.047 |
|
| 2021 |
Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. PMID 34247197 DOI: 10.1038/s41375-021-01343-w |
0.047 |
|
| 2011 |
Kryukov F, Dementyeva E, Smetana J, Sevcikova S, Kuglik P, Hajek R. Association of aneuploidy category with centrosome amplification in multiple myeloma. Leukemia & Lymphoma. 52: 2020-2. PMID 21635202 DOI: 10.3109/10428194.2011.587561 |
0.045 |
|
| 2022 |
Adam Z, Řehák Z, Adamová Z, Koukalová R, Pour L, Krejčí M, Boichuk I, Krejčí M, Štork M, Ševčíková S, Král Z. Unicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitrni Lekarstvi. 67: 465-473. PMID 35459366 |
0.042 |
|
| 2022 |
Adam Z, Řehák Z, Adamová Z, Koukalová R, Pour L, Krejčí M, Boichuk I, Sandecká V, Krejčí M, Štork M, Ševčíková S, Král Z. Multicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitrni Lekarstvi. 68: 41-53. PMID 35459346 |
0.039 |
|
| 2015 |
Adam Z, Szturz P, Krejčí M, Vašků V, Pour L, Michalková E, Ševčíková S, Čermáková Z, Veselý K, Vaníček J, Pourová E, Král Z, Mayer J. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies]. Vnitr̆Ní LéKar̆Ství. 61: 1072-87. PMID 26806503 |
0.037 |
|
| Hide low-probability matches. |